Kodiak Sciences Inc Common Stock (KOD)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 124
- Market Cap
- $2.7B
About Kodiak Sciences Inc Common Stock
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
SentiSense also tracks daily options readings for Kodiak Sciences Inc Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Kodiak Sciences Inc Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.